embecta and Tidepool partner to develop automated insulin delivery system for people with Type 2 diabetes
12 Mai 2023 - 12:15PM
Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest
pure-play diabetes care companies in the world, and Tidepool, a
501(c)(3) nonprofit organization committed to harnessing the power
of technology to provide intuitive software products that help
people living with diabetes, have announced that the two
organizations will partner to develop an automated insulin delivery
(AID) system for people living with type 2 diabetes (T2D).
embecta will leverage Tidepool’s expertise in
diabetes management software to develop the AID algorithm for its
closed-loop patch pump system designed with the specific needs of
people living with T2D, for which it received FDA Breakthrough
Device Designation.
"A large segment of the diabetes community is
made up of people living with T2D, however, the existing AID
systems are not tailored to meet their unique needs," said Henry
Anhalt, DO, Chief Medical Officer, embecta. "The recent 510(k)
clearance of Tidepool Loop — a fully interoperable automated
insulin dosing app which started as a patient-led initiative —
affirms that Tidepool’s approach to AID system development combines
patient insights with a robust diabetes management solution. We
believe that the combination of the embecta and Tidepool teams will
lead to the development of a user-centric T2D AID system that fills
a need for improved glucose management.”
"By partnering with Tidepool and tapping into
their expertise on AID software development, we’re continuing our
effort to deliver a user-friendly patch pump solution that will
make life better for people living with T2D," said Devdatt (Dev)
Kurdikar, Chief Executive Officer of embecta.
"We are committed to helping all people with
insulin-requiring diabetes safely achieve improved outcomes," said
Howard Look, Founder and Chief Executive Officer of Tidepool.
"Building on the recent FDA clearance for Tidepool Loop, Tidepool
is excited to partner with embecta to create tailored solutions for
a broader user base including people with type 2 diabetes."
About embectaembecta is one of
the largest pure-play diabetes care companies in the world,
leveraging its nearly 100-year legacy in insulin delivery to
empower people with diabetes to live their best life through
innovative solutions, partnerships and the passion of approximately
2,000 employees around the globe. For more information, visit
embecta.com or follow our social channels on LinkedIn, Facebook,
Instagram and Twitter.
About TidepoolTidepool is a
recognized innovator in diabetes software on a mission to make
diabetes data more accessible, actionable, and meaningful for
people with diabetes, their care teams, and researchers. Founded in
2013, Tidepool hosts a suite of software tools for people with
diabetes and the clinics that serve them, including Tidepool Web,
Tidepool Mobile, Tidepool Uploader, and Tidepool Loop. Tidepool is
a registered 501(c)3 nonprofit organization. Learn more at
tidepool.org. Follow us on Twitter at @Tidepool_org and on Facebook
and Instagram.
Contacts:
MediaChristian
GlazarSr. Director, Corporate Communications908-821-6922Contact
Media Relations |
Investors
Pravesh KhandelwalVP, Head of Investor Relations551-264-6547Contact
IR |
Embecta (NASDAQ:EMBCV)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Embecta (NASDAQ:EMBCV)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024